- Home
- SILO
SILO
Silo Pharma Inc.
as 07-26-2024 4:00pm EST
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 3.5M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 15.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $4.50 | Next Earning Date: | 05-13-2024 |
| Revenue: | $72,102 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 1.86% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Silo Pharma Inc. (SILO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weisblum Eric | SILO | CEO and President | Jun 11 '24 | Buy | $1.11 | 4,438 | $4,926.18 | 180,432 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Jun 11 '24 | Buy | $1.08 | 562 | $606.96 | 175,994 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Apr 4 '24 | Buy | $1.96 | 600 | $1,176.00 | 175,032 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Apr 4 '24 | Buy | $2.03 | 400 | $812.00 | 175,432 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Mar 28 '24 | Buy | $1.91 | 1,100 | $2,101.00 | 174,432 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Mar 28 '24 | Buy | $1.94 | 3,408 | $6,611.52 | 173,332 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Dec 19 '23 | Buy | $1.63 | 500 | $815.00 | 169,724 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Dec 19 '23 | Buy | $1.61 | 200 | $322.00 | 169,924 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Dec 14 '23 | Buy | $1.52 | 900 | $1,368.00 | 169,224 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Dec 14 '23 | Buy | $1.50 | 200 | $300.00 | 168,324 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Dec 5 '23 | Buy | $1.39 | 600 | $834.00 | 167,724 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Dec 5 '23 | Buy | $1.34 | 76 | $101.84 | 167,800 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Dec 5 '23 | Buy | $1.36 | 324 | $440.64 | 168,124 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Nov 29 '23 | Buy | $1.57 | 1,000 | $1,570.00 | 166,124 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Nov 29 '23 | Buy | $1.53 | 1,000 | $1,530.00 | 167,124 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Nov 20 '23 | Buy | $1.60 | 4,050 | $6,480.00 | 164,174 | SEC Form 4 |
| Weisblum Eric | SILO | CEO and President | Nov 20 '23 | Buy | $1.56 | 300 | $468.00 | 164,474 | SEC Form 4 |
Latest Silo Pharma Inc. News
SILO Breaking Stock News: Dive into SILO Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 hours ago
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
GlobeNewswire
4 days ago
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
7 days ago
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
8 days ago
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
GlobeNewswire
11 days ago
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
GlobeNewswire
18 days ago
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
GlobeNewswire
a month ago
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
GlobeNewswire
2 months ago
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
Compare SILO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SILO Silo Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.